TY  - JOUR
AU  - Abad, A
AU  - Martinez-Balibrea, E
AU  - Vieitez, J M
AU  - Alonso-Orduña, V
AU  - Garcia Alfonso, P
AU  - Manzano, J L
AU  - Massuti, B
AU  - Benavides, M
AU  - Carrato, A
AU  - Zanui, M
AU  - Gallego, J
AU  - Gravalos, C
AU  - Conde, V
AU  - Provencio, M
AU  - Valladares-Ayerbes, M
AU  - Salazar, R
AU  - Sastre, J
AU  - Montagut, C
AU  - Rivera, F
AU  - Aranda, E
PY  - 2017
DO  - 10.1093/annonc/mdx737
UR  - http://hdl.handle.net/10668/11804
T2  - Annals of oncology : official journal of the European Society for Medical Oncology
AB  - There has been little progress toward personalized therapy for patients with metastatic colorectal cancer (mCRC). TYMS-3' untranslated region (UTR) 6 bp ins/del and ERCC1-118C/T polymorphisms were previously reported to facilitate selecting patients...
LA  - en
PB  - Elsevier
KW  - Colorectal cancer
KW  - Polymorphisms
KW  - Biomarkers
KW  - Bevacizumab
KW  - Oxaliplatin
KW  - Irinotecan
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic combined chemotherapy protocols
KW  - Biomarkers, tumor
KW  - Colorectal neoplasms
KW  - DNA-binding proteins
KW  - Endonucleases
KW  - Female
KW  - Genotype
KW  - Humans
KW  - Male
KW  - Middle aged
KW  - Patient selection
KW  - Pharmacogenomic testing
KW  - Pharmacogenomic variants
KW  - Precision medicine
KW  - Progression-free survival
KW  - Thymidylate synthase
KW  - Treatment outcome
TI  - Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial.
TY  - Research article
VL  - 29
ER  -